Gennady Landa, MD, is vice chair, clinical integration of ophthalmology, Mount Sinai Health System; director of retina service, NYEEI; and associate professor of ophthalmology, vitreoretinal surgeon ...

When no retina podcast was available, Jayanth Sridhar, MD, created one—and learned lessons about branding, bandwidth, and mentorship along the way. In this installment, Eichenbaum talks with Jayanth ...

Imaging and biomarkers are driving earlier, more individualized GA treatment Imaging is critical to early diagnosis. Autofluorescence is invaluable for diagnosing GA and following disease progression.

Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care. This year in retina is almost ...

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability. The panel reviews why ...

Campbell is the Edwin and Josephine Knowles Endowed Professor of Ophthalmology and professor at the Casey Eye Institute, Oregon Health & Science University in Portland. Campbell notes he is affiliated ...

An expert demonstrates how to safely co-manage AMD and GA using staggered dual-pathway treatment to maintain stability and patient confidence. Dr. Sambhara presents an 87-year-old male with geographic ...

Dr. Singh reported that when technicians understand why they are performing a diagnostic test, they perform better and think critically in patient care situations.

The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space. Modern imaging technologies, like advanced forms of optical coherence ...

During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy.

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...